Bispecific Antibody Induces High Response Rate in Metastatic TNBC

(MedPage Today) — SAN ANTONIO — More than 70% of patients with advanced triple-negative breast cancer (TNBC) responded to an investigational bispecific antibody targeting PD-L1 and VEGF-A plus chemotherapy, a preliminary study showed.
Overall…